biodefense
-
Emergent Wins Additional $51.9M for Smallpox Countermeasure Under US Biodefense Contract or US Awards Emergent $51.9M More for Smallpox Treatment in Biodefense Push or Emergent Secures $51.9M Boost to Supply VIGIV Smallpox Treatment for US Preparedness
Emergent BioSolutions secured a $51.9M U.S. government contract extension to supply smallpox vaccine complication treatment CNJ-016®, reinforcing its role in national biodefense. The 10-year ASPR partnership highlights Emergent’s dominance in the $10B U.S. medical countermeasures market, where government deals drive 85% of its revenue. While the deal boosts supply chain security and manufacturing credibility, VIGIV carries clinical risks including thrombosis, renal issues, and blood product transmission concerns. The contract underscores Emergent’s strategic positioning in pandemic preparedness amid growing demand for specialized, domestically produced countermeasures, balancing revenue stability with operational challenges.
